Novartis Ag (NVSEF) Change in Intangibles (2009 - 2026)

Novartis Ag's (NVSEF) quarterly Change in Intangibles came in at -$461.0 million in Q1 2026, down 12.99% quarter-over-quarter from -$408.0 million in Q4 2025.

Novartis Ag (NVSEF) Change in Intangibles (2009 - 2026) Analysis & Trends

Novartis Ag has disclosed Change in Intangibles across 12 years of filings, most recently posting -$461.0 million for Q1 2026.

  • Change in Intangibles for Q1 2026 came in at -$461.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 billion (changed N/A YoY), and the FY2025 annual result was $164.0 million, up 105.0% from the prior year.
  • Change in Intangibles came in at -$461.0 million for Q1 2026 at Novartis Ag, down from -$408.0 million in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of -$192.0 million in Q4 2022 to a low of -$929.0 million in Q1 2024.
  • The 5-year median for Change in Intangibles is -$441.5 million (2023), against an average of -$442.8 million.
  • Across the five-year window, Change in Intangibles soared 63.29% in 2023 and tumbled 320.36% in 2024, its largest moves.
  • Novartis Ag's Change in Intangibles stood at -$192.0 million in 2022, then slumped by 96.35% to -$377.0 million in 2023, then sank by 51.99% to -$573.0 million in 2024, then advanced by 28.8% to -$408.0 million in 2025, then decreased by 12.99% to -$461.0 million in 2026.
  • The last three Change in Intangibles figures came in at -$461.0 million (Q1 2026), -$408.0 million (Q4 2025), and -$477.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Intangibless (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -299.30 Mn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -
10 Novartis Ag - - - -461.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -461.00 Mn
Mar 31, 2026 -461.00 Mn
Dec 31, 2025 -408.00 Mn
Dec 31, 2025 -408.00 Mn
Sep 30, 2025 -477.00 Mn
Sep 30, 2025 -477.00 Mn
Jun 30, 2025 -227.00 Mn
Jun 30, 2025 -227.00 Mn
Dec 31, 2024 -573.00 Mn
Dec 31, 2024 -573.00 Mn
Sep 30, 2024 -478.00 Mn
Sep 30, 2024 -478.00 Mn
Jun 30, 2024 -468.00 Mn
Jun 30, 2024 -468.00 Mn
Mar 31, 2024 -929.00 Mn
Mar 31, 2024 -929.00 Mn
Dec 31, 2023 -377.00 Mn
Dec 31, 2023 -377.00 Mn
Sep 30, 2023 -422.00 Mn
Sep 30, 2023 -422.00 Mn